Saturday, March 28, 2020 6:03:32 PM
A CBC article regarding British Columbia COVID-19 news mentions that BC is doing trials with anti-viral drugs. See Bonnie Henry's comment at the end of this article:
https://www.cbc.ca/news/canada/british-columbia/bc-covid-19-update-saturday-1.5513615
"The provincial health officer also confirmed that B.C. has been using anti-malarial and anti-viral AIDS drugs in trials at one facility, although she didn't confirm where".
Sounds familiar...:)
For those that don't know, Lexaria's lab and offices are in Kelowna, British Columbia.
Recently Lexaria has entered the battle to fight COVID-19 as per these news releases:
https://www.lexariabioscience.com/news/lexaria-bioscience-begins-coronavirus-covid-19-drug-delivery-program/
https://www.lexariabioscience.com/news/lexaria-bioscience-expands-pharmaceutical-division-to-include-lipophilic-antiviral-active-molecules-for-covid-19-treatment/
https://www.cbc.ca/news/canada/british-columbia/bc-covid-19-update-saturday-1.5513615
"The provincial health officer also confirmed that B.C. has been using anti-malarial and anti-viral AIDS drugs in trials at one facility, although she didn't confirm where".
Sounds familiar...:)
For those that don't know, Lexaria's lab and offices are in Kelowna, British Columbia.
Recently Lexaria has entered the battle to fight COVID-19 as per these news releases:
https://www.lexariabioscience.com/news/lexaria-bioscience-begins-coronavirus-covid-19-drug-delivery-program/
https://www.lexariabioscience.com/news/lexaria-bioscience-expands-pharmaceutical-division-to-include-lipophilic-antiviral-active-molecules-for-covid-19-treatment/
Recent LEXX News
- Lexaria Bioscience Releases Second Episode of Investor Video Series • ACCESS Newswire • 05/07/2026 01:25:00 PM
- Lexaria Updates Progress on Human Study #7 • ACCESS Newswire • 05/05/2026 01:10:00 PM
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications • ACCESS Newswire • 05/01/2026 01:25:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 04/29/2026 01:10:00 PM
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs • ACCESS Newswire • 04/23/2026 01:05:00 PM
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales • ACCESS Newswire • 04/21/2026 01:10:00 PM
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property • ACCESS Newswire • 04/15/2026 01:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 05:07:36 PM
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval • ACCESS Newswire • 04/07/2026 01:10:00 PM
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
